Optimizing direct-acting antiviral treatment for hepatitis c virus through pharmacist interventions
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Poster
- By: CHIEN, Wei-Hsuan (Cheng Hsin General Hospital)
- Co-author(s): Wei-Hsuan Chien
Treatment for hepatitis C virus (HCV) has evolved dramatically since the approval of all-oral direct-acting antivirals (DAAs). DAAs are majorly metabolized by liver enzymes and influence the activity of cytochrome P450 (CYP) enzymes. In addition, DAAs are both substrates and inhibitors of drug transporters, which increases the likelihood.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.